You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Cipla receives USFDA nod for Firazyr generic

Capital Market 

The drug major on Tuesday (14 July) said it received final approval for its abbreviated new drug application (ANDA) for Icatibant injectable from the United States Food and Drug Administration (USFDA).

Cipla's Icatibant injectable pre-filled syringe is AP-rated generic version of Shire's Firazyr. It is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

According to IQVIA (IMS Health), Firazyr and its generic equivalents had US sales of approximately $270 million for the 12-month period ending May 2020.

Meanwhile, Cipla on Monday (13 July) announced that the discussions to renegotiate the deal between Cipla's US subsidiary CipTech and Pulmatrix Inc for the co-development and commercialization of antifungal drug Pulmazole, are now in progress. The renegotiated agreement may include, amongst other things a reallocation of costs and a grant of rights to CipTec to develop and commercialize Pulmazole in select markets outside the United States, Cipla said in a regulatory filing.

Cipla is a global pharmaceutical company focused on complex generics, and deepening portfolio in India, South Africa, North America, and key regulated and emerging markets.

On a consolidated basis, the drug maker's net profit declined 33% to Rs 245.95 crore on a 0.7% rise in net sales to Rs 4301.60 crore in Q4 March 2020 over Q4 March 2019.

The scrip rose 0.72% to trade at Rs 642.75 on the BSE. It has traded in the range of Rs 639 and Rs 642.85 so far during the day.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 14 2020. 09:18 IST